Four insights:
1. Generex acquired 61 percent of Olaregen Therapeutix. The company’s Excellagen wound care product is a 3D wound conforming model.
2. The company acquired regenerative medicine company Regentys, which developed a non-surgical treatment option for Ulcerative Colitis — ExtraCellular Matrix Hydrogel.
3. The company also acquired Veneto Assets, Pantheon Medical, Kiromonic and MediSource Partners and completed the 100 percent acquisition of HDS, which is now called NuGenerix Diagnostics.
4. In April 2019, Generex bolstered its board of directors with two independent appointments, Mark Prioletti and Omar Gzouli.
More articles on devices:
Cerapedics expands Colorado HQ — 3 things to know
HSS acquires low-dose orthopedic imaging system — 3 insights
Medtronic secures market-leading position through Titan Spine acquisition, analyst says
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.